drugset / Trial / NCT04334967

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

NCT04334967

RandomizedParallel-groupSingle-blindTreatment

Summary

This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19

Timeline

Start
2020-03-30
Primary completion
2021-05-27
Completion
2022-05-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject Vitamin C Other / unclassified 500 mg Oral

Indications